Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

BACKGROUND: Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cun, Gao, Dongmei, Guo, Kun, Kang, Xiaonan, Jiang, Kai, Sun, Chun, Li, Yan, Sun, Lu, Shu, Hong, Jin, Guangzhi, Sun, Haiyan, Wu, Weizhong, Liu, Yinkun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469344/
https://www.ncbi.nlm.nih.gov/pubmed/22559167
http://dx.doi.org/10.1186/1471-2407-12-166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469344/
https://www.ncbi.nlm.nih.gov/pubmed/22559167
http://dx.doi.org/10.1186/1471-2407-12-166

Ejemplares similares